U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Clouded Minds Vape Shoppe - 557861 - 10/18/2018
  1. Warning Letters

CLOSEOUT LETTER

Clouded Minds Vape Shoppe MARCS-CMS 557861 —

Delivery Method:
Electronic Mail
Reference #:
RW1800913

Recipient:
Recipient Name
Anton Snegiroff and Alexander Kovalev
Clouded Minds Vape Shoppe
Clouded Minds Vape Shoppe

United States

info@cloudedmindsvape.com, MR.SCORP666@gmail.com
Issuing Office:
Center for Tobacco Products

10903 New Hampshire Avenue
Silver Spring , MD 20993
United States


Dear Anton Snegiroff and Alexander Kovalev:

On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Chill Purple Grape e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. The Warning Letter also informed you that this product is misbranded under section 903(a)(7)(B) because you sold it to a person younger than 18 years of age, in violation of 21 C.F.R. § 1140.14(b)(1). Specifically, FDA determined that the labeling and/or advertising of your Chill Purple Grape e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. FDA also determined that a person younger than 18 years of age was able to purchase Chill Purple Grape e-liquid from your website.

On September 12, 2018, you sent FDA a response to the Warning Letter, and we held a teleconference on October 3, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other re levant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.

Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.

Sincerely,
/S/

Elle Ibarra-Pratt

Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
U.S. Food & Drug Administration
Center for Tobacco Products

VIA Electronic Mail

cc:

GoDaddy.com, LLC
abuse@godaddy.com

VPS Datacenter, LLC
securitv@vpsdatacenter.com